STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Clinical trials for STAGE IIIC CUTANEOUS MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIC CUTANEOUS MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIC CUTANEOUS MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests Double-Drug attack on tough skin cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug combination for advanced melanoma that has spread or cannot be surgically removed. It combines pembrolizumab, an immunotherapy drug, with ibrutinib, a drug that may block cancer cell growth. The goal is to s…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
Boosting the Body's army: can a second drug help immune therapy fight deadly melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF (sargramostim) to an existing immune-boosting cancer drug (ipilimumab) could help patients with advanced melanoma live longer. The trial involved 245 adults whose melanoma could not be removed by surgery. Researchers compared …
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Drug combo shrinks tumors before surgery, aims to stop Cancer's return
Disease control OngoingThis study tested a two-part drug treatment for people with stage IIIB or IIIC melanoma that has a specific genetic change (BRAF V600 mutation). Patients took the drugs dabrafenib and trametinib for 8 weeks before surgery to try to shrink the tumor, then continued the drugs for a…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major cancer trial tests new immune therapy to keep deadly skin cancer at bay
Disease control OngoingThis large study aimed to find the best treatment to prevent melanoma skin cancer from returning after it has been surgically removed. It compared a newer immune-boosting drug called ipilimumab against the standard treatment, interferon. Over 1,600 patients with high-risk melanom…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Three-Drug attack on Tough-to-Treat skin cancer
Disease control OngoingThis study is testing two different combinations of three drugs to see if they are safe and effective for people with advanced melanoma that has a specific genetic change (BRAF mutation) and has spread or cannot be removed by surgery. The goal is to control the cancer by using an…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Scientists test malaria drug combo against tough cancers
Disease control OngoingThis early-stage trial is testing whether combining an experimental cancer drug called MK-2206 with the malaria drug hydroxychloroquine is safe for people with advanced solid tumors, melanoma, kidney, or prostate cancer. The main goal is to find the highest dose patients can tole…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test new drug duo in fight against tough tumors
Disease control OngoingThis early-stage study is testing the safety and best dose of two drugs, riluzole and sorafenib, when given together. It's for people with advanced solid tumors or melanoma that have spread and are no longer responding to standard treatments. The goal is to see if this combinatio…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Two-Drug combo tested in fight against advanced skin cancer
Disease control OngoingThis study tested whether adding high-dose interferon to the immunotherapy drug ipilimumab helps control advanced melanoma better than ipilimumab alone. It also compared two different doses of ipilimumab. The trial involved 88 adults with stage III or IV melanoma that couldn't be…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists supercharge Patients' own cells to battle deadly skin cancer
Disease control OngoingThis early-stage study is testing the safety of a new personalized treatment for advanced melanoma. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, and then infuse them back into the body. The goal is to see if th…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New combo therapy fights back when melanoma outsmarts standard treatment
Disease control OngoingThis study is testing whether a two-part immunotherapy can help patients with advanced melanoma whose cancer has continued to grow despite standard immune-based treatments. It combines a modified virus injected directly into tumors (T-VEC) with an intravenous drug (pembrolizumab)…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 18:34 UTC